

New research shows asthma drug's effectiveness over usual care alone

13 September 2017, by Amy Mcsweeney



And at 24 weeks, a significantly higher percentage of patients with symptomatic [asthma](#) and initiated on treatment with FF/VI achieved better control of their asthma (71%), compared with patients continuing usual care treatment (56%), (odds ratio 2.00, 95% CI 1.70, 2.34; p

Credit: University of Plymouth

A new study co-authored by the University of Plymouth and published in *The Lancet* shows how an asthma drug was more effective at improving a patient's asthma control compared with their usual care.

The study was developed by pharmaceutical company GlaxoSmithKline (GSK), and showed that a once-daily inhalation of a powder, made up of drugs fluticasone furoate and 25mg Vilanterol (FF/VI), was noticeably more effective at improving scores in a test of [asthma control](#), using a validated tool – the Asthma Control Test (ACT), than taking regular maintenance inhaler therapy alone.

Regular maintenance inhaler therapy is defined as taking [inhaled corticosteroids](#) (ICS) on their own, or in combination with a long-acting beta-agonist (LABA).

Commercially known as Relvar Ellipta, the [drug](#) was given to 2,114 of 4,233 [patients](#) for the study, with results monitored at 12, 24, 40 and 52 weeks.

APA citation: New research shows asthma drug's effectiveness over usual care alone (2017, September 13) retrieved 18 November 2017 from <https://medicalxpress.com/news/2017-09-asthma-drug-effectiveness-usual.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.